Evidence map›Paper›PMID 39433741›Full record

ArticleBlood cancer journal2024

Publisher Correction: Patient preferences for intervention in the setting of precursor multiple myeloma.

Catherine R Marinac, Katelyn Downey, Jacqueline Perry, Brittany Fisher-Longden, Timothy R Rebbeck, Urvi A Shah, Elizabeth K O'Donnell, Irene M Ghobrial, Omar Nadeem, Brian L Egleston

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Catherine R MarinacDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US. catheriner_marinac@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-9128-3012
Katelyn DowneyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.ORCID http://orcid.org/0000-0002-8782-4971
Jacqueline PerryDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.
Brittany Fisher-LongdenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.
Timothy R RebbeckDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.ORCID http://orcid.org/0000-0002-4799-1900
Urvi A ShahDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, US.ORCID http://orcid.org/0000-0001-8419-1091
Elizabeth K O'DonnellDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.
Irene M GhobrialDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.ORCID http://orcid.org/0000-0001-7361-3092
Omar NadeemDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.
Brian L EglestonFox Chase Cancer Center, Philadelphia, PA, US.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39433741
PMCPMC11493951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.